MET and non-small cell lung carcinoma: MET amplification in NSCLC may be a primary oncogenic alteration or may arise as a secondary driver resistance mechanism to EGFR TKI treatment through the activation of downstream signaling pathways, like MAPK or PI3K-Akt (98, 101).